Compare Dropbox Inc (DBX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Dropbox Inc trades at $34.15 (market cap $7.42B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 3,061,580). Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| DBX | XBI | |
|---|---|---|
Market Cap | $7.42B | $10.11B |
Volume | 3,061,580 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $37.74 | $169.55 |
52-Week Low | $22.06 | $104.99 |
Typical Hold Time | 97 Days | 37 Days |
Enterprise Value | $10.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $33.08, down 1.93% today, showing bearish technical signals with resistance at $34. Fundamentally, the company maintains strong profitability with 79.72% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights insider selling and a security breach affecting 5,000 accounts in August 2026, while analyst sentiment remains divided with a consensus price target of $26.83.
The outlook remains cautious due to mixed analyst ratings and insider selling activity. While strong cash flow generation and consistent earnings beats provide support, valuation concerns and stagnant revenue growth near $2.5B present headwinds. Key risks include competitive pressures in cloud storage and execution challenges in maintaining market position.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
